A combination of rituximab, lenalidomide, and ibrutinib produced a high overall response rate (ORR), and the triplet regimen with chemotherapy resulted in durable responses in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to results from the Smart Start study. The Smart Start study is the first study to treat newly diagnosed DLBCL with a targeted therapy combination before chemotherapy. The results were published in the Journal of Clinical Oncology in a paper by Jason Westin, MD, MS, of the University of Texas MD Anderson Cancer Center in Houston and colleagues. ...
Advertisement
Ibrutinib treatment was associated with higher survival rates in patients with mantle cell lymphoma (MCL) and CNS relapse.
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
Nicholas Short, MD, on his hopes for the new year in blood cancer.
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Assistant Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Expert Interviews
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
American Society of Hematology
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
Raul Cordoba, MD, PhD
Raul Cordoba, MD, PhDKey Points. Fully automated classification of mature
flowcytometry
hematology
lymsm
Frontiers
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
Benlazar S M A
Benlazar S M AAllogeneic stem cell transplantation still represent
aml
leusm
finance.yahoo.com
FDA Puts Clinical Hold On Gilead’s Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MSThe FDA has placed a partial clinical hold on Gilead
leusm
mdssm
medRxiv
Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional
Michael Hallek
Michael HallekBackground Long COVID is a post-severe acute respira
longcovid
ACUTE MYELOID LEUKEMIA
AGGRESSIVE B-CELL LYMPHOMA
CHRONIC LYMPHOCYTIC LEUKEMIA
MYELOMA
ACUTE MYELOID LEUKEMIA
